Fullerenes: In vivo studies of biodistribution, toxicity, and biological action

Nanotechnologies in Russia

Volumn 9, Issue 11-12, 2014, Pages 601-617

  Hendrickson, O D ^a   Zherdev, A V ^a   Gmoshinskii, I V ^b   Dzantiev, B B ^a  

^a BACH INSTITUTE OF BIOCHEMISTRY   (Russian Federation)

^b FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

Author keywords

biological action; fullerene; in vivo; toxicity

Indexed keywords

BIOACTIVITY; INDUSTRIAL POISONS; METABOLISM; RESPIRATORY SYSTEM; TOXICITY;

BIOLOGICAL ACTIONS; GASTROINTESTINAL TRACT; IN-VIVO; INTRAPERITONEAL ADMINISTRATION; METABOLIC PATHWAYS; PATHOLOGICAL LESIONS; PHYSICOCHEMICAL PROPERTY; STANDARDIZED PROCEDURE;

FULLERENES;

EID: 84914102683     PISSN: 19950780     EISSN: 19950799     Source Type: Journal    
DOI: 10.1134/S199507801406010X     Document Type: Article

References (132)

1. A. Demming, “The state of research after 25 years of Nanotechnology,” Nanotechnology 25(1), 010201 (2013).
2. H. L. I. Bouwmeester, H. J. P. Marvin, K. A. Dawson, M. Berges, D. Braguer, H. J. Byrne, A. Casey, G. Chambers, M. J. Clift, G. Elia, T. F. Fernandes, L. B. Fjellsbo, P. Hatto, L. Juillerat, C. Klein, W. G. Kreyling, C. Nickel, M. Riediker, and V. Stone, “Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices,” Nanotoxicology 5(1), 1–11 (2011).
3. J. R. Z. Peralta-Videa, M. L. Lopez-Moreno, G. de la Rosa, J. Hong, and J. L. Gardea-Torresdey, “Nanomaterials and the environment: a review for the biennium 2008–2010,” J. Hazard Mater. 186(1), 1–15 (2011).
4. H. Bouwmeester, S. Dekkers, M. Y. Noordam, W. I. Hagens, A. S. Bulder, C. de Heer, S. E. C. G. ten Voorde, S. W. P. Wijnhoven, H. J. P. Marvin, and A. J. A. M. Sips, “Review of health safety aspects of nanotechnologies in food production,” Regul. Toxicol. Pharmacol. 53(1), 52–62 (2009).
5. N. Feliu and B. Fadeel, “Nanotoxicology: no small matter,” Nanoscale 2(12), 2514–2520 (2010).
6. H. Alenius, J. Catalán, H. Lindberg, H. Norppa, J. Palomäki, and K. Savolainen, “Chapter 3-nanomaterials and human health, in Handbook of Nanosafety, Eds. by U. Vogel, et al. (Academic Press, San Diego, 2014), pp. 59–133.
7. H. Johnston, G. Pojana, S. Zuin, N. R. Jacobsen, P. Moller, S. Loft, M. Semmler-Behnke, C. McGuiness, D. Balharry, A. Marcomini, H. Wallin, W. Kreyling, K. Donaldson, L. Tran, and V. Stone, “Engineered nanomaterial risk. Lessons learnt from completed nanotoxicology studies: potential solutions to current and future challenges,” Crit. Rev. Toxicol. 43(1), 1–20 (2013).
8. A. Seaton, L. Tran, R. Aitken, and K. Donaldson, “Nanoparticles, human health hazard and regulation,” J. Royal Soc. Interface 7(1), 119–129 (2010).
9. J. M. Davis, “A comprehensive environmental assessment approach to engineered nanomaterials,” Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5(2), 139–149 (2013).
10. A. Trpkovic, B. Todorovic-Markovic, and V. Trajkovic, “Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress,” Arch. Toxicol. 86(12), 1809–1827 (2012).
11. K. Aschberger, H. J. Johnson, V. Stone, R. J. Aitken, C. L. Tran, S. M. Hankin, S. A. Peters, and F. M. Christensen, “Review of fullerene toxicity and exposure-appraisal of a human health risk assessment, based on open literature,” Regul. Toxicol. Pharmacol. 58(3), 455–473 (2010).
12. “List of representative manufactured nanomaterials for testing-OECD,” http://www.oecd.org/env/ehs/nanosafety/List-of-representative-MN-for-testing-Nov-2012.pdf.
13. H. W. Kroto, J. R. Heath, and S. C. O’Brien, “C60: Buckminsterfullerene,” Nature 318(6042), 162–163 (1985).
14. V. I. Sokolov and I. V. Stankevich, “Fullerenes-new allotropic form of carbon: structure, electronic structure and chemical properties,” Usp. Khim. 62(5), 455–473 (1993).
15. E. N. Karaulova and E. I. Bagrii, “Fullerenes: methods of functionalization and perspectives of derivatives’ application,” Usp. Khim. 68(11), 979–998 (1999).
16. M. Prato, A. Bianco, M. Maggini, G. Scorrano, C. Toniolo, and F. Wudl, “Synthesis and characterization of the first fullerene-peptide,” J. Org. Chem. 58(21), 5578–5580 (1993).
17. S. Yamago, H. Tokuyama, E. Nakamura, M. Prato, and F. Wudl, “Chemical derivatization of organofullerenes through oxidation, reduction, and carbonoxygen and carbon-carbon bond-forming reactions,” J. Org. Chem. 58(18), 4796–4798 (1993).
18. J. W. Arbogast, A. P. Darmanyan, C. S. Foote, F. N. Diederich, R. L. Whetten, Y. Rubin, M.M. Alvarez, and S. J. Anz, “Photophysical properties of sixty atom carbon molecule (C60),” J. Phys. Chem. 95(1), 11–12 (1991).
19. C. S. Foote, “Photophysical and photochemical properties of fullerenes,” in Electron Transfer, Ed. by I. J. Mattay (Springer Berlin Heidelberg, 1994), pp. 347–363.
20. 60,” Science 254(5035), 1183–1185 (1991).
21. H. Barry and M. C. John, Free Radical in Biology and Medicine, 4th ed. (Oxford University Press, 2006).
22. V. N. Bezmelnitsin, A. V. Eletskii, and M. V. Okun’, “Fullerenes in Solutions,” Usp. Fiz. Nauk 168(11), 1195–1220 (1998).
23. R. S. Ruoff, D. S. Tse, L. Malhotra Ripudaman, and C. Donald, “Solubility of fullerene (C60) in a variety of solvents,” J. Phys. Chem. 97(13), 3379–3383 (1993).
24. N. O. Mchedlov-Petrossyan, “Fullene solutions: colloidal aspect,” Khimiya, fizika ta tekhnologiya poverkhni 1(1), 19–37 (2010).
25. N. O. Mchedlov-Petrossyan, “Fullerenes in molecular liquids. Solutions in “good” solvents: another view,” J. Mol. Liquids 161(1), 1–12 (2011).
26. N. O. Mchedlov-Petrossyan, “Fullerenes in liquid media: an unsettling intrusion into the solution chemistry,” Chem. Rev. 113(7), 5149–5193 (2013).
27. 70,” Chem. Phys. Lett. 360(5–6), 422–428 (2002).
28. 60,” Chem. Phys. Lett. 327(3–4), 143–148 (2000).
29. V. N. Bezmelnitsin, A. V. Eletskii, and E. V. Stepanov, “Cluster origin of fullerene solubility,” J. Phys. Chem. 98(27), 6665–6667 (1994).
30. 60into artificial lipid membranes,” J. Am. Chem. Soc. 115(8), 3386–3387 (1993).
31. 60in model biological systems. A visible-UV absorption study of solvent-dependent parameters and solute aggregation,” J. Phys. Chem. 98(13), 3492–3500 (1994).
32. K. N. Semenov, N. A. Charykov, and O. V. Arapov, “The solubility of fullerenes in n-alkanols-1,” Russ. J. Phys. Chem. A, Focus on Chemistry 82(8), 1318–1326 (2008).
33. 60in nonionic Triton X-100 micelles,” Carbon 46(4), 692–698 (2008).
34. Y. Tabata, Y. Murakami, and Y. Ikada, “Photodynamic effect of polyethylene glycol-modified fullerene on tumor,” Jpn. J. Cancer Res. 88(11), 1108–1116 (1997).
35. Y. N. Yamakoshi, T. Yagami, K. Fukuhara, S. Sueyoshi, and N. Miyata, “Solubilization of fullerenes into water with polyvinylpyrrolidone applicable to biological tests,” J. Chem. Soc. Chem. Commun. 4, 517–518 (1994).
36. 60in micellar solutions of different solubilizers,” Colloids & Surfaces B: Biointerfaces 82(1), 46–53 (2011).
37. 60,” J. Chem. Soc. Perkin Trans. 2, 191–196 (2001).
38. C. N. Murthy, S. J. Choi, and K. E. Geckeler, “Nanoencapsulation of [60] fullerene by a novel sugar-based polymer,” J. Nanosci. Nanotechnol. 2(2), 129–132 (2002).
39. 70by complexation with cyclomaltononaose (delta-cyclodextrin),” Pharmazie 63(1), 54–57 (2008).
40. R. G. Alargova, Sh. Deguchi, and K. Tsujii, “Stable colloidal dispersions of fullerenes in polar organic solvents,” J. Am. Chem. Soc. 123(43), 10460–10467 (2001).
41. L. K. Duncan, J. R. Jinschek, and P. J. Vikesland, “C60 colloid formation in aqueous systems: effects of preparation method on size, structure, and surface charge,” Environ. Sci. Technol. 42(1), 173–178 (2007).
42. G. V. Andrievsky, M. V. Kosevich, O. M. Vovk, V. S. Shelkovsky, and L. A. Vashchenko, “On the production of an aqueous colloidal solution of fullerenes,” J. Chem. Soc. Chem. Commun. (12), 1281–1282 (1995).
43. 60) nanoparticles in monovalent and divalent electrolyte solutions,” J. Colloid Interface Sci. 309(1), 126–134 (2007).
44. 60in water by data of small angle neutron scattering,” J. Mol. Liquids 127(1)–(3), 73–78 (2006).
45. D. Y. Lyon, L. K. Adams, J. C. Falkner, and P. J. J. Alvarez, “Antibacterial activity of fullerene water suspensions: effects of preparation method and particle size,” Environ. Sci. Technol. 40(14), 4360–4366 (2006).
46. 60derivatives,” Environ. Sci. Tech. 43(17), 6597–6603 (2009).
47. D. M. Guldi, “Capped fullerenes: stabilization of water-soluble fullerene monomers as studied by flash photolysis and pulse radiolysis,” J. Phys. Chem. A 101(21), 3895–3900 (1997).
48. “Guidance on sample preparation and dosimetry for the safety testing of manufactured nanomaterials: ENV/JM/MONO(2012)40,” Directorate Series on the Safety of Manufactured Nanomaterials (OECD, Environmen, Paris, 2012), no. 36.
49. I. Gitsov, A. Simonyan, L. Wang, A. Krastanov, S. W. Tanenbaum, and D. Kiemle, “Polymer-assisted biocatalysis: unprecedented enzymatic oxidation of fullerene in aqueous medium,” J. Polym. Sci. A Polym. Chem. 50(1), 119–126 (2011).
50. A. B. Seabra, A. J. Paula, and N. Durán, “Redoxenzymes, cells and micro-organisms acting on carbon nanostructures transformation: a mini-review,” Biotechnol. Prog. 29(1), 1–10 (2013).
51. M. Calvaresi and F. Zerbetto, “Fullerene sorting proteins,” Nanoscale 3(7), 2873–2881 (2011).
52. 60: a new form of carbon,” Nature 347(6291), 354–358 (1990).
53. O. D. Hendrickson, I. V. Safenkova, A. V. Zherdev, B. B. Dzantiev, and V. O. Popov, “Methods of detection and identification of manufactured nanoparticles,” Biophysics 56(6), 961–986 (2011).
54. P. A. Troshin, H. Hoppe, A. S. Peregudov, M. Egginger, S. Shokhovets, G. Gobsch, N. S. Sariciftci, and V. F. Razumov, “[70]fullerene-based materials for organic solar cells,” Chem. Sus. Chem. 4(1), 119–124 (2011).
55. B. C. Thompson and J. M. Frechet, “Polymer-fullerene composite solar cells,” Angew. Chem. Int. Ed. Engl. 47(1), 58–77 (2008).
56. P. Anilkumar, F. Lu, L. Cao, P. G. Luo, J. H. Liu, S. Sahu, K. N. Tackett, Y. Wang, and Y. P. Sun, “Fullerenes for applications in biology and medicine,” Curr. Med. Chem. 18(14), 2045–2059 (2011).
57. 82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy,” Integr. Biol. (Camb.) 5(1), 43–47 (2013).
58. T. N. Mashino, D. Nishikawa, K. Takahashi, N. Usui, T. Yamori, M. Seki, T. Endo, and M. Mochizuki, “Antibacterial and antiproliferative activity of cationic fullerene derivatives,” Bioorg. Med. Chem. Lett. 13(24), 4395–4397 (2003).
59. 60and derivatives in orthopaedic research,” Connect. Tissue Res. 55(2), 71–79 (2014).
60. Y. Fujitani, T. Kobayashi, K. Arashidani, N. Kunugita, and K. Suemura, “Measurement of the physical properties of aerosols in a fullerene factory for inhalation exposure assessment,” J. Occup. Environ. Hyg. 5(6), 380–389 (2008).
61. P. H. Hoet, I. Bruske-Hohlfeld, and O. V. Salata, “Nanoparticles-known and unknown health risks,” J. Nanobiotech. 2(1), 12–27 (2004).
62. M. Lens, “Use of fullerenes in cosmetics,” Recent Pat. Biotechnol. 3(2), 118–123 (2009).
63. T. G. Smijs and J. A. Bouwstra, “Focus on skin as a possible port of entry for solid nanoparticles and the toxicological impact,” J. Biomed. Nanotechnol. 6(5), 469–484 (2010).
64. M. H. Al-Hallak, M. K. Sarfraz, S. Azarmi, W. H. Roa, W. H. Finlay, and R. Lobenberg, “Pulmonary delivery of inhalable nanoparticles: dry powder inhalers,” Ther. Deliv. 2(10), 1313–1324 (2011).
65. C. S. Yah, G. S. Simate, and S. E. Iyuke, “Nanoparticles toxicity and their routes of exposures,” Pak. J. Pharm. Sci. 25(2), 477–491 (2012).
66. A. M. Nystrom and B. Fadeel, “Safety assessment of nanomaterials: implications for nanomedicine,” J. Control Release 161(2), 403–408 (2012).
67. J. Zhao and V. Castranova, “Toxicology of nanomaterials used in nanomedicine,” J. Toxicol. Environ. Health B Crit. Rev. 14(8), 593–632 (2011).
68. H. Wang, S. T. Yang, A. Cao, and Y. Liu, “Quantification of carbon nanomaterials in vivo,” Acc. Chem. Res. 46(3), 750–760 (2013).
69. G. G. Onishchenko, I. V. Bragina, O. I. Aksenova, T. Yu. Zavistyaeva, A. L. Mishina, V. A. Tutelyan, I. V. Gmoshinskii, S. A. Khotimchenko, et al., “Procedure for assessing the toxic effect of nanomaterials in laboratory animals,” Methodical Instructions. MU 1.2.2869-11 (Federal Center of Hygiene and Epidemiology of Pospotrebnadzor, Moscow, 2011) [in Russian].
70. 60), intratracheal instillation, or intravenous injection in male F344 rats,” in Society of Toxicology Annual Meeting, March 15–19 2009, Baltimore, MD, USA.
71. 60exposure,” Toxicol. Sci. 118(2), 564–573 (2010).
72. 60fullerene from the lung into the blood circulation in the mouse: possible association of diffusion and caveolae-mediated pinocytosis,” Toxicol. Pathol. 37(4), 456–462 (2009).
73. 60fullerene particles,” Toxicology 258(1), 47–55 (2009).
74. 60fullerene nanoparticles and microparticles,” Toxicol. Sci. 101(1), 122–131 (2008).
75. 60,” Bioorg. Chem. 24(4), 376–385 (1996).
76. S. Yamago, H. Tokuyama, E. Nakamura, K. Kikuchi, S. Kananishi, K. Sueki, H. Nakahara, S. Enomoto, and F. Ambe, “In vivo biological behavior of a watermiscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity,” Chem. Biol. 2(6), 385–389 (1995).
77. 60nanocrystals,” Nanotechnology 20(38), 385102 (2009).
78. xin mice,” J. Nanoparticle Res. 8(1), 53–63 (2006).
79. 60exposure on the biochemical profile of urine,” J. Appl. Toxicol. 30(4), 354–360 (2010).
80. T. T. Mori, H. Takada, S. Ito, K. Matsubayashi, N. Miwa, and T. Sawaguchi, “Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis,” Toxicology 225(1), 48–54 (2006).
81. N. Gharbi, M. Pressac, M. Hadchouel, H. Szwarc, S. R. Wilson, and F. Moussa, “[60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity,” Nano Lett. 5(12), 2578–2585 (2005).
82. 60in rats,” Toxicol. Pathol. 26(1), 143–151 (1998).
83. B. B. Dzantiev, S. G. Klochkov, O. D. Hendrikson, A. V. Zherdev, and S. O. Bachurin, “Study of nanoparticles localization in organs and tissues of rats after intraperitoneal and intragastrical administration,” Abstracts of the Conference “Nanosafe-2012”, November 13–15, 2012 (Grenoble, France), p. O2b-1.
84. 60peroral toxicity to rats in the 92-day experiment,” Vopr. Pit. (5), 20–27 (2012) [in Russian].
85. 60) topically exposed in industrial organic solvents,” Toxicol. Appl. Pharmacol. 242(1), 29–37 (2010).
86. S. Kato, H. Aoshima, Y. Saitoh, and N. Miwa, “Highly hydroxylated or gamma-cyclodextrin-bicapped watersoluble derivative of fullerene: the antioxidant ability assessed by electron spin resonance method and betacarotene bleaching assay,” Bioorg. Med. Chem. Lett. 19(18), 5293–5296 (2009).
87. 60/liposome complex: defensive effects against UVA-induced damages in skin structure, nucleus and collagen type I/IV fibrils, and the permeability into human skin tissue,” J. Photochem. Photobiol. B 98(1), 99–105 (2010).
88. G. G. Onishchenko, I. V. Bragina, O. I. Aksenova, V. Yu. Smolensky, T. Yu. Zavistyaeva, V. A. Tutelyan, I. V. Gmoshinskii, et al., “Procedure of biomedical evaluation of nanomaterials’ effects in laboratory animals by morphological indicators and metabolic parameters,” Methodical Instructions. MU 1.2.2965-11 (Federal Center of Hygiene and Epidemiology of Rospotrebnadzor, Moscow, 2011) [in Russian].
89. G. G. Onishchenko, I. V. Bragina, T. Yu. Zavistyaeva, V. à. Tutelyan, I. V. Gmoshinskii, S. A. Khotimchenko, et al., “Procedure for the detection and identification of nanomaterials in laboratory animals,” Methodical Instructions. MU 1.2.2874-1124 (Federal Center of Hygiene and Epidemiology of Rospotrebnadzor, Moscow, 2011) [in Russian].
90. V. A. Tutelyan, I. V. Gmoshinskii, S. A. Khotimchenko, M. M. Gapparov, L. S. Vasilevskaya, et al., “Procedures and methods for determining the organotropy and toxicokinetic parameters of engineered nanomaterials in tests on laboratory animals,” Guidelines. MR 1.2.0048-11 (Federal Center of Hygiene and Epidemiology of Rospotrebnadzor, Moscow, 2011) [in Russian].
91. G. G. Onishchenko, I. V. Bragina, T. Yu. Zavistyaeva, V. A. Tutelyan, I. V. Gmoshinskii, S. A. Khotimchenko, et al., “Identification of priority nanomaterials in the environment, living organisms and food,” Guidelines. MR 1.2.2641-10 (Federal Center of Hygiene and Epidemiology of Rospotrebnadzor, Moscow, 2010) [in Russian].
92. Guidelines for Pre-clinical Trials of Drugs. Part One, Ed. by A. N. Mironov (Griff & Co. Moscow, 2012) [in Russian].
93. OECD, Test No. 405: Acute Eye Irritation/Corrosion: OECD Publishing.
94. OECD, Test No. 443: Extended One-Generation Reproductive Toxicity Study: OECD Publishing.
95. OECD, Test No. 429: Skin Sensitisation: OECD Publishing.
96. OECD, Test No. 403: Acute Inhalation Toxicity: OECD Publishing.
97. OECD, Test No. 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents: OECD Publishing.
98. OECD, “Guidance on sample preparation and dosimetry for the safety testing of manufactured nanomaterials,” Series on the Safety of Manufactured Nanomaterials, No. 36: OECD publishing.
99. G. Oberdorster, “Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology,” J. Intern. Med. 267(1), 89–105 (2010).
100. G. Oberdorster, E. Oberdorster, and J. Oberdorster, “Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles,” Environ. Health Perspect. 113(7), 823–839 (2005).
101. 60fullerene from the lung into the blood circulation in the mouse: possible association of diffusion and caveolae-mediated pinocytosis,” Toxicol. Pathol. 7(4), 456–462 (2009).
102. 60fullerene particles,” Toxicology 258(1), 47–55 (2009).
103. Y. Morimoto, M. Hirohashi, A. Ogami, T. Oyabu, T. Myojo, K. Nishi, C. Kadoya, M. Todoroki, M. Yamamoto, M. Murakami, M. Shimada, W. N. Wang, K. Yamamoto, K. Fujita, S. Endoh, K. Uchida, N. Shinohara, J. Nakanishi, and I. Tanaka, “Inflammogenic effect of well-characterized fullerenes in inhalation and intratracheal instillation studies. Part,” Fibre Toxicol. 7, 4 (2010).
104. A.Y. Ogami, K. Yamamoto, Y. Morimoto, K. Fujita, M. Hirohashi, T. Oyabu, T. Myojo, K. Nishi, C. Kadoya, M. Todoroki, M. Yamamoto, M. Murakami, M. Shimada, W. N. Wang, N. Shinohara, S. Endoh, K. Uchida, J. Nakanishi, and I. Tanaka, “Pathological features of rat lung following inhalation and intratracheal instillation of C(60) fullerene,” Inhal. Toxicol. 23(7), 407–416 (2011).
105. 60water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles,” Nano Lett. 7(8), 2399–2406 (2007).
106. 60s) can induce inflammatory responses in the lung of mice,” Toxicol. Appl. Pharmacol. 244(2), 226–233 (2010).
107. N. R. Jacobsen, P. Moller, K. A. Jensen, U. Vogel, O. Ladefoged, S. Loft, and H. Wallin, “Lung inflammation and genotoxicity following pulmonary exposure to nanoparticles in ApoE-/-mice. Part,” Fibre Toxicol. 6, 2 (2009).
108. 60fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice,” Basic Clin. Pharmacol. Toxicol. 103(4), 386–388 (2008).
109. J. Y. Xu, K. Han, S. X. Li, J. S. Cheng, G. T. Xu, W. X. Li, and Q. N. Li, “Pulmonary responses to polyhydroxylated fullerenols, C(60)(OH)(x),” J. Appl. Toxicol. 29(7), 578–584 (2009).
110. 60fullerenes and single-walled carbon nanotubes,” Environ. Health Perspect. 117(5), 703–708 (2009).
111. 60in rats,” J. Toxicol. Sci. 37(2), 353–361 (2012).
112. 60after oral administration,” Pharmazie. 68(1), 54–57 (2013).
113. 60administered to the rat gastrointestinal tract,” Gig. Sanit. 2, 90–94 (2012).
114. 60) in 28-day in vivo experiment,” Nanotechnologies in Russia 8(11)–(12), 799–809 (2013).
115. A. Huczko, H. Lange, and E. Calko, “Short communication: fullerenes: experimental evidence for a null risk of skin irritation and allergy,” Fullerene Sci. Technol. 7(5), 935–939 (1999).
116. J. H. Draize, G. Woodard, and H. O. Calvery, “Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes,” J. Pharmacol. Exp. Then. 82, 377–390 (1944).
117. H. S. Aoshima, Y. Saytoh, S. Ito, S. Yamana, and N. Miwa, “Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage,” J. Toxicol. Sci. 4(5), 555–562 (2009).
118. S. Ito, K. Itoga, M. Yamato, H. Akamatsu, and T. Okano, “The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin,” Toxicology 267(1)–(3), 27–38 (2010).
119. 60nanoparticles in a comet assay using lung cells of intratracheally instilled rats,” Regul. Toxicol. Pharmacol. 62(3), 419–424 (2012).
120. M. A. Nelson, F. E. Domann, G. T. Bowden, S. B. Hooser, Q. Fernando, and D. E. Carter, “Effects of acute and subchronic exposure of topically applied fullerene extracts on the mouse skin,” Toxicol. Ind. Health. 9(4), 623–630 (1993).
121. N. S. Zogovic, N. S. Nikolic, S. D. Vranjes-Djuric, L.M. Harhaji, L. M. Vucicevic, K. D. Janjetovic, M. S. Misirkic, B. M. Todorovic-Markovic, Z. M. Markovic, S. K. Milonjic, and V. S. Trajkovic, “Opposite effects of nanocrystalline fullerene (C(60)) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C(60),” Biomaterials 30(36), 6940–6946 (2009).
122. 60,” Toxicol. Lett. 93(1), 29–37 (1997).
123. 60(OH)22 on doxorubicin-induced cytotoxicity,” Toxicology in Vitro 18(5), 629–637 (2004).
124. V. D. Milic, K. Stankov, R. Injac, A. Djordjevic, B. Srdjenovic, B. Govedarica, N. Radic, V. D. Simic, and B. Strukelj, “Activity of antioxidative enzymes in erythrocytes after a single dose administration of doxorubicin in rats pretreated with fullerenol C(60)(OH)(24),” Toxicol. Mech. Methods 19(1), 24–28 (2009).
125. T. O. Tsuchiya, I. Oguri, Y. N. Yamakoshi, and N. Miyata, “Novel harmful effects of [60]fullerene on mouse embryos in vitro and in vivo,” FEBS Lett. 393(1), 139–145 (1996).
126. N. A. Monteiro-Riviere, K. E. Linder, A. O. Inman, J. G. Saathoff, X. R. Xia, and J. E. Riviere, “Lack of hydroxylated fullerene toxicity after intravenous administration to female Sprague-Dawley rats,” J. Toxicol. Environ. Health A 75(7), 367–373 (2012).
127. 60) nanoparticles,” Environ. Toxicol. Chem. 25(4), 1132–1137 (2006).
128. 60) induce oxidative stress in the brain of juvenile largemouth bass,” Environ. Health Perspect. 112(10), 1058–1062 (2004).
129. 60nano-aggregates to tetrahydrofuran decomposition products in larval zebrafish by assessment of gene expression,” Environ. Health Perspect. 115(7), 1059–1065 (2007).
130. 60preparations: role of THF peroxide,” Environ. Sci. Technol. 43(1), 108–113 (2009).
131. 60) in two aquatic species, Daphnia and fathead minnow,” Mar. Environ. Res. 62, S5–S9 (2006).
132. 60uncovers mechanisms of nanotoxicity disrupting the native conformations of DNA/RNA,” Nucleic Acids Res. 40(16), 7622–7632 (2012).